ASN Launches Glomerular Diseases Collaborative

The American Society of Nephrology (ASN) has launched the Glomerular Diseases Collaborative (GD-C) to promote high quality care for people with glomerular diseases and stimulate opportunities to address gaps in knowledge, training, continuing education, and awareness across the spectrum of glomerular diseases.

The ASN GD-C Strategic Advisory Panel was formed in 2023 to explore, analyze, and evaluate the diagnosis and treatment landscape for glomerular diseases and identify opportunities to address gaps in care, research, and education. The ASN GD-C Steering Committee will build upon the strategic advisory panel’s framework and develop interventions to improve early identification of patients with glomerular diseases, expand clinical knowledge, advocate for improved access to specialists and clinical trials, and promote equitable access to the best treatments.

“We want this group to be driven by the mission of making sure that all people with glomerular disease, regardless if you are a farmer living in the rural Midwest, a professor living in a large metropolitan city, or a child, your access to the best care and treatment is the same,” said Keisha Gibson, MD, MPH, FASN, GD-C chair.

Amgen, Otsuka, Travere Therapeutics, and Vera Therapeutics have provided support for the GD-C.